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Obesity-induced inflammation is critical for the
development of insulin resistance. Here, we show
that genetic inactivation of PKCz in vivo leads to a hy-
perinflammatory state in obese mice that correlates
with a higher glucose intolerance and insulin
resistance. Previous studies implicated PKCz in the
regulation of type 2 inflammatory responses in
T cells. By using ex vivo and in vivo experiments,
we demonstrate that although PKCz is involved in
the alternative (M2) activation of macrophages,
surprisingly, PKCz ablation in the nonhematopoietic
compartment but not in the hematopoietic system
is sufficient to drive inflammation and IL-6 synthesis
in the adipose tissue, as well as insulin resistance.
Experiments using PKCz/IL-6 double-knockout
mice demonstrated that IL-6 production accounts
for obesity-associated glucose intolerance induced
by PKCz deficiency. These results establish PKCz
as a critical negative regulator of IL-6 in the control
of obesity-induced inflammation in adipocytes.
INTRODUCTION
Research on the molecular signaling pathways that control
obesity and that regulate adipocyte development and differenti-
ation, food intake, and energy combustion has attracted much
attention due to the potential of this work to provide new strate-
gies for the prevention and treatment of obesity and associated
diseases, such as glucose intolerance and type 2 diabetes (Flier,
2004). Several of the signaling molecules that have been impli-
cated in the pathophysiology of obesity were primarily known
for their roles in the control of cell growth, differentiation, and
apoptosis (Fajas et al., 2002; Flier, 2004; Hirosumi et al., 2002;
Kim et al., 2004b; Matsumoto et al., 2003; Molero et al., 2004;Nakae et al., 2003; Suzawa et al., 2003; Um et al., 2004).
However, recent studies highlight the importance of inflamma-
tion, characterized by infiltration of macrophages and the secre-
tion of inflammatory cytokines in metabolically active tissues, in
the induction of glucose intolerance and insulin resistance during
obesity (Hotamisligil, 2006; Qatanani and Lazar, 2007; Sabio
et al., 2008; Schenk et al., 2008; Shoelson et al., 2006). Adoptive
transfer studies have suggested the primary role of the hemato-
poietic system in insulin resistance in high-fat diet (HFD)-induced
obesity (Saberi et al., 2009; Solinas et al., 2007). Also, the abla-
tion of macrophages normalizes insulin sensitivity in obesity
(Patsouris et al., 2008), whereas genetic inactivation of PPARg
or PPARd in macrophages leads to the inhibition of the alterna-
tive activation (also known as type 2 inflammation) of resident
macrophages in liver and adipose tissue, which results in a tonic
type 1 hyperinflammatory state and subsequent glucose intoler-
ance and impaired insulin responses in obese mice (Kang et al.,
2008; Odegaard et al., 2008). Furthermore, other investigators
have presented compelling in vivo evidence on the role of T
lymphocytes and mast cells in this process (Feuerer et al.,
2009; Liu et al., 2009; Nishimura et al., 2009; Winer et al.,
2009). Therefore, a paradigm is emerging, according to which
signaling molecules controlling macrophage and/or T cell func-
tion could be excellent therapeutic targets in type 2 diabetes.
Contrary to this model, recent data in JNK-deficient mice
indicate that inflammatory signals from adipocytes, but not from
the hematopoietic system, are the key players in inflammation-
induced insulin resistance in obesity (Sabio et al., 2008). That is,
recent elegant studies using bone-transfer chimeras and condi-
tional JNK knockout mice show that secretion of IL-6 by adipo-
cytes, but not bymacrophages, is what is essential for the control
of insulin resistance in obese mice (Sabio et al., 2008). It is likely
that, depending on the signaling cascade, the hematopoietic
system and/or the stroma play different roles in these processes.
The identification of the signaling molecules utilized by the
different cellular components involved in this phenomenon will
be instrumental for the design of better therapies.
The atypical PKC isoform, PKCz, has been implicated in the
control of two critical inflammatory cascades (Moscat et al.,Cell Metabolism 12, 65–77, July 7, 2010 ª2010 Elsevier Inc. 65
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transactivating subunit of the canonical NF-kB complex, PKCz
modulates kB-dependent transcription in fibroblasts activated
by TNF-a and IL-1 (Duran et al., 2003; Leitges et al., 2001).
PKCz also phosphorylates Jak1, a critical player in IL-4 signaling
(Dura´n et al., 2004; Martin et al., 2005). This might account for its
implication in Th2-dependent inflammation (Moscat et al.,
2006b). Therefore, PKCz could play a dual role in inflammation:
(1) a proinflammatory role through the activation of NF-kB and
type 1 responses or (2) a critical regulatory role in the type 2
anti-inflammatory response through the IL-4/Stat6 cascade. As
obesity leads to a tonic hyperinflammatory response character-
ized by an increase in type 1 versus type 2 inflammation, we
hypothesized that PKCz might be critical in the regulation of
the balance between the two types of inflammatory responses
during obesity-induced inflammation and the induction of
glucose intolerance and insulin resistance.
RESULTS
Impaired Insulin Sensitivity in HFD-Fed PKCz/ Mice
As glucose intolerance and insulin resistance are key features
of the metabolic syndrome (Semenkovich, 2006; Shoelson
et al., 2006), and inflammation plays an important role in this
phenomenon (Hotamisligil, 2006; Shoelson et al., 2006), we
have evaluated whether PKCz deficiency would lead to
increased inflammation and the ensuing systemic glucose intol-
erance and insulin resistance in the context of fat accumulation.
To address this question, we have used PKCz-deficient mice.
Figure 1A shows the genotype of PKCz/ mice, which lack
the PKCz allele, as described previously (Leitges et al., 2001).
Results shown in Figure 1B demonstrate that PKCz is actually
lost, as determined by immunoblotting in different tissues,
and that PKCz is abundantly expressed in white adipose tissue
(WAT) at levels comparable to those of lung and liver and, to
a lesser degree, in BAT and muscle. Therefore, PKCz is
expressed in metabolically relevant tissues, and its genetic
ablation results in the expected lack of its protein expression.
We then performed glucose tolerance tests (GTTs) in WT and
PKCz/ mice that had been fed a HFD or regular diet (RD)
for 12 weeks. WT mice kept under HFD-fed conditions dis-
played reduced glucose clearance in response to a bolus of
glucose, as compared with WT mice fed in parallel with RD
(Figure 1C). PKCz/mice fed with RD displayed glucose clear-
ance similar to that of identically treated WT mice (Figure 1C),
indicating that the loss of PKCz does not affect glucose metab-
olism under normal conditions. However, glucose clearanceFigure 1. Development of Insulin Resistance in HFD-Fed PKCz/ Mic
(A) Genotypic analysis of mice by PCR.
(B) PKCz protein expression in different tissues from wild-type (WT) and PKCz/
(C) Glucose tolerance test (GTT).
(D) Insulin tolerance test (ITT).
(E) Glucose-stimulated insulin secretion was measured in WT and PKCz/ mice
(F) Resting blood insulin was examined in WT and PKCz/ mice fed a regular d
(G) Fasting blood glucose levels.
(H–L) Hepatic gluconeogenic gene expression. PGC-1a, peroxisome proliferator
phatase (I); and PEPCK, phosphoenolpyruvate carboxykinase (J) are shown. Bo
HFD for 12 weeks. Data are mean ±SEM of 6 or 7 animals per group. *p < 0.05 vwas much more impaired in PKCz-deficient mice when fed
a HFD than in identically treated WT mice or RD-fed WT or
PKCz/ mice (Figure 1C). These results indicate that even
though PKCz does not play a major role in glucose clearance
under RD-fed conditions, HFD feeding makes PKCz/ mice
highly glucose intolerant. This could indicate a higher level of
insulin resistance upon HFD feeding in PKCz/ mice. In
keeping with this notion, although glucose clearance in
response to insulin injection (ITT) was significantly impaired
only at 15 min postinjection in HFD-fed WT mice as compared
to RD-fed WT mice, it was dramatically worsened at all time
points in HFD-fed PKCz-deficient mice as compared to identi-
cally treated WT mice (Figure 1D). This is indicative of insulin
resistance in the HFD-fed PKCz knockout mouse group. In
contrast, there were no differences between WT and PKCz-
deficient mice in terms of ITT when they have been fed with
RD (Figure 1D). Previous data indicated that the atypical
PKCs could be involved in glucose metabolism and insulin
action (Farese and Sajan, 2010). However, our GTT and ITT
data demonstrate that under normal RD feeding conditions,
PKCz does not play such a role in vivo, and that if any atypical
PKC is involved in that process, it is more likely to be PKCl/i
(Farese et al., 2007).
These results suggest that although PKCz is not required for
normal in vivo insulin action in RD-fed mice, its lack in HFD-fed
mice leads to enhanced insulin resistance. In keeping with this,
blood insulin levels were dramatically increased in HFD-fed
PKCz-deficient mice upon glucose injection, as compared to
identically treated WT mice (Figure 1E). Consistently, Figure 1F
demonstrates increased basal nonfasting blood insulin levels in
HFD-fed PKCz/ mice. Fasting glucose levels were increased
in HFD-fed PKCz/ mice as compared to identically fed WT
mice or RD-fed WT and PKCz/ mice, although the latter also
showed a noticeable, but not statistically significant, increase
in levels of glucose as compared to WT controls (Figure 1G).
It should be noted that the levels of gluconeogenic genes in
WT and PKCz-deficient livers did not differ when mice were
fed a HFD (Figures 1H–1J). Although the expression of these
genes was reduced in PKCz/ livers as compared with WT in
mice fed a RD (Figures 1H–1J), this alteration did not seem to
affect the basal fasting glucose levels (Figure 1G) nor the
response to GTT or ITT (Figures 1C and 1D).
All these results suggest that the loss of PKCz exacerbates
HFD-induced glucose intolerance and insulin resistance, but
no differences were observed in body weight, fat content, or
blood leptin levels in PKCz-deficient mice fed a HFD as
compared with identically treated WT mice, although HFDe
 mice.
fed a HFD for 12 weeks.
iet (RD) or HFD as above.
-activated receptor gamma coactivator-1 alpha (H); G6Pase, glucose 6 phos-
dy weights (K) and grams of total fat (L) were measured in mice fed a RD or
ersus WT.
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Figure 2. Reduced Glucose Metabolism and Insulin Signaling in HFD-Fed PKCz/ Mice
(A) A 2 hr hyperinsulinemic-euglycemic clamp was performed in conscious mice following exposure to HFD for 12 weeks. Glucose infusion rates, whole-body
glucose turnover, and HGP were measured at basal levels (prior to insulin clamp) and during the insulin-stimulated state. Tissues were taken at the end of the
clamp experiments to assess insulin-stimulated glucose uptake in skeletal muscle (gastrocnemius), heart, and white and brown adipose tissues. Data are ex-
pressed as mean ±SEM of 5 or 6 animals per group. *p < 0.05 versus WT.
(B) Mice were fasted overnight and treated with insulin (5 U/kg body weight) for 10 min by intraperitoneal injection. Liver, WAT, and muscle tissues were isolated
and examined by western blot analysis using antibodies to phospho-AKT, AKT, and actin.
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feeding in WT mice (Figures 1K and 1L). The levels of circulating
TAG, NEFA, and cholesterol were dramatically induced by HFD
in WT mice as compared to RD-fed WT mice and were signifi-
cantly higher in HFD-fed PKCz-deficient mice (Table S1).
To determine the effects of PKCz deficiency on glucose
metabolism in individual organs, we performed a 2 hr hyperinsu-
linemic-euglycemic clamp in conscious PKCz/ mice and
WT littermates following HFD feeding (Kim et al., 2004a)
(Figure 2A). The steady-state glucose infusion rates required to
maintain euglycemia during the clamps were significantly
reduced in HFD-fed PKCz/ mice as compared with HFD-fed
WT mice. Insulin-stimulated whole-body glucose turnover rates
were reduced by 40% in HFD-fed PKCz/ mice. Basal rates
of hepatic glucose production (HGP) were not altered, but
HGP rates during insulin clamping tended to be higher in HFD-
fed PKCz/ mice, resulting in lower hepatic insulin action in68 Cell Metabolism 12, 65–77, July 7, 2010 ª2010 Elsevier Inc.these mice. Insulin-stimulated glucose uptake in skeletal muscle
and heart were markedly reduced in HFD-fed PKCz/ mice.
Glucose uptake in WAT was not significantly altered, but brown
adipose tissue glucose uptake was reduced by more than 50%
in HFD-fed PKCz/mice. Taken together, these results indicate
that PKCz deficiency exacerbates insulin resistance in peripheral
organs and liver following HFD.
To further characterize insulin resistance in these mice, they
were injected with insulin for 10 min, after which they were sacri-
ficed and extracts were prepared from liver, WAT, and muscle.
Akt activation was determined by immunoblotting with an anti-
phospho-Akt antibody. Interestingly, Akt activation was normal
in liver and WAT of PKCz/ mice fed a RD (Figure 2B). There
was a significant reduction in Akt activation in muscle from
RD-fed PKCz/ mice as compared with identically treated WT
mice (Figure 2B), consistent with the evidence that PKCz plays
a role in Akt activation, at least in some tissues (Joshi et al.,
Figure 3. IncreasedMacrophage Infiltration and Hepatic Steato-
sis in HFD-Fed PKCz/ Mice
(A andB) Epididymal adipose tissues (A) and interscapular adipose tissues
(B) were isolated from WT and PKCz/ mice fed a RD or HFD for 12
weeks.
(C) Epididymal adipose tissue sections were stained with hematoxylin and
eosin.
(D) Adipocyte area was evaluated in around 500 cells in sections of epidid-
ymal adipose tissue from three different animals per group.
(E) Sections of epididymal adipose tissue used for measurements in (D)
immunostained against F4/80.
(F and G) The expression of the CD68 and F4/80 was examined by quan-
titative RT-PCR in epididymal adipose tissue.
(H) Gross liver morphology.
(I) Liver weights were measured in mice fed a RD or HFD for 12 weeks.
(J) Liver sections stained with hematoxylin and eosin.
(K) Liver triglyceride contents measured by using an enzymatic method
(Randox). Scale bars, 200 mm. Data are mean ±SEM of 6 or 7 animals
per group. *p < 0.05 versus WT.
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but not in WAT in WT mice (Figure 2B). However, the most
striking observation was the dramatic impairment of Akt activa-
tion in the liver of HFD-fed PKCz/mice as compared with iden-
tically treated WT mice (Figure 2B). These data are consistent
with a model whereby the loss of PKCz increases insulin resis-
tance in HFD-fed mice, especially in the liver.
Role of PKCz in Obesity-Induced Inflammation
The fact that PKCz-deficient mice fed a HFD showed enhanced
insulin resistance and impaired glucose tolerance suggested
that the lack of PKCz might lead to enhanced inflammation,which has previously been shown to play a major role in
obesity-induced insulin resistance and glucose intolerance.
Therefore, in the next series of experiments, we analyzed
whether PKCz deficiency promotes inflammation during
HFD-induced obesity. Adipose tissue and liver are the two
tissues in which obesity-induced inflammation has been
shown to develop and that play a major role in glucose
metabolism. Interestingly, morphological analysis of WAT
(epididymal fat pads) (Figure 3A) and brown adipose tissue
(BAT) (interscapular depots) (Figure 3B) from HFD-fed WT
and PKCz-deficient mice demonstrate similar adipose tissue
volume in both mouse genotypes, although they were signif-
icantly bigger than the same tissues from mice fed a RD
(Figures 3A and 3B). Similar results were obtained when the
weights of these tissues were compared (data not shown).
Histological analysis of hematoxylin and eosin (H&E)-stained
tissue sections revealed increased adipocyte size in WAT
from HFD-fed PKCz/ mice as compared to identically
treated WT controls (Figure 3C, lower panels, and
Figure 3D), whereas no differences were apparent between
the WAT from RD-fed mice of different genotypes
(Figure 3C, upper panels, and Figure 3D). Although HFD
feeding enhanced the adipocyte size of WT mice as
compared with RD feeding, the effect of HFD on PKCz-defi-
cient mice was greater than in WT mice (Figures 3C and 3D).
More importantly, WAT from HFD-fed PKCz/ mice but not
from HFD-fed WT mice or from RD-fed mice of either geno-
type displayed a dramatic increase in macrophage infiltration,
as assessed by staining with anti-F4/80 antibody (Figure 3E).
This observation was confirmed by RT-PCR analysis of CD68
and F4/80 mRNAs in these tissues (Figures 3F and 3G). These
results indicate that feeding a HFD to PKCz-deficient mice leads
to an inflammatory response in WAT that is not apparent in iden-
tically treated WT mice.
Morphological and histological analysis revealed a significant
increase in the size and weight of HFD-fed PKCz/mouse livers
as compared to identically treated WT mice or RD-fed mice of
both genotypes (Figures 3H and 3I). This correlated with
enhanced lipid accumulation, as determined by histologicalCell Metabolism 12, 65–77, July 7, 2010 ª2010 Elsevier Inc. 69
Table 1. Inflammatory Signature in Adipose Tissue
RD HFD
WT PKCz/ WT PKCz/
IL-6 3.3 ± 0.3 3.6 ± 0.3 4.0 ± 0.2 8.2 ± 1.2a
TNF-a 2.3 ± 0.1 2.3 ± 0.4 3.1 ± 0.2 7.4 ± 0.6 a
INFg 2.7 ± 0.4 2.6 ± 0.4 3.3 ± 0.4 6.8 ± 0.6 a
IL-4 3.7 ± 0.4 1.8 ± 0.3 a 3.5 ± 0.4 4.2 ± 0.2
IL-13 3.8 ± 0.5 3.3 ± 0.5 6.0 ± 1.6 7.0 ± 1.4
Arg1 1.7 ± 0.4 2.5 ± 0.5 1.6 ± 1.6 2.8 ± 0.3
Mgl2 2.7 ± 0.4 3.1 ± 0.7 6.8 ± 0.9 2.4 ± 0.3 a
NOS 2.2 ± 0.7 2.6 ± 0.3 3.4 ± 0.7 6.9 ± 0.7 a
WAT expression of inflammatory genes in age-matched wild-type (WT)
and PKCz KO mice (6 of each phenotype) fed either a regular diet (RD)
for 5 months or an RD for 2 months followed by a HFD for 3 months.
a p < 0.05 PKCz/ versus WT. Values are expressed as mean ±SEM.
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HFD-fed PKCz-deficient mice, although it was also detected to
a lesser extent in RD-fed PKCz/ mice (Figures 3J and 3K).
We did not detect changes in liver triglyceride secretion
(Figure S1A) or in the expression levels of, for example, LDLR
(Figure S1B). Consistent with this fatty liver phenotype, we de-
tected significantly increased hepatic expression levels of the
adipogenic/lipogenic genes PPARg, PGC-1b, FAS, C/EBPb,
and ACC without changes in the expression levels of SREBP-
1c or C/EBPb in PKCz/ mice as compared with WT mice,
with both genotypes fed a HFD (Figures S1C–S1I). These alter-
ations were not apparent when livers of the two genotypes
were compared under a RD feeding regime (Figures S1C–S1I).
The increase in the levels of adipogenic/lipogenic enzymes in
the liver of HFD-fed PKCz-deficient mice might contribute to
the fatty liver phenotype observed in these mice. However, we
did not detect macrophage infiltration in these livers (data not
shown). These data demonstrate that the targeted deletion of
PKCz leads to selective WAT inflammation when mice are fed
a HFD, which is not observed in WT mice. Therefore, the lack of
PKCz sensitizes the adipose tissue to inflammation driven by
HFD intake, which correlates with fatty liver, glucose intolerance,
and insulin resistance.
Recent data demonstrate that adipocytes secrete type 2 cyto-
kines, such as IL-4, that skew adipose tissue macrophages
(ATMs) toward an anti-inflammatory type 2 (also known as M2)
profile. In contrast to the proinflammatory type 1 profile (also
known as M1), the M2 profile limits inflammation in vivo via
reduced tissular secretion of proinflammatory cytokines
(Gordon, 2003; Kang et al., 2008; Odegaard et al., 2008; Vats
et al., 2006). This is important because an increased M1/M2
cytokine ratio has been proposed to be responsible for insulin
resistance during obesity (Kang et al., 2008; Odegaard et al.,
2008). Therefore, we tested the hypothesis that PKCz deficiency
could tilt the balance of adipose tissue polarization toward anM1
proinflammatory phenotype that could account for the higher
insulin resistance and glucose intolerance observed in the
HFD-fed PKCz-deficient mice. To do this, we analyzed the
expression of a series of inflammatory genes in WAT from
HFD-fed WT and PKCz-deficient mice. Interestingly, as shown
in Table 1, WAT from HFD-fed PKCz/ mice displayed70 Cell Metabolism 12, 65–77, July 7, 2010 ª2010 Elsevier Inc.increased levels of the proinflammatory cytokines IL-6, TNF-a,
and IFNg as compared with WAT from identically treated WT
mice. In contrast, levels of the Th2 cytokines, IL-4 and IL-13,
were unaltered (Table 1). HFD feeding did not affect the adipose
tissue cytokine signature of WT mice (Table 1). Also, no changes
other than a decrease in IL-4 synthesis were detected when this
parameter was analyzed in PKCz-deficient adipose tissue as
compared to WT under RD feeding conditions (Table 1). There-
fore, HFD feeding leads to a hyperinflammatory state in
PKCz/ WAT that might account for the glucose intolerance
observed in these mice when fed a HFD. Because IL-4 is
secreted by adipocytes and T cells and targets resident macro-
phages to drive them into an M2 anti-inflammatory phenotype
(Kang et al., 2008; Odegaard et al., 2008), our results suggest
that PKCz deficiency does not affect the secretion of IL-4 in
HFD-fedmice, but that it might be important for its actions. Inter-
estingly, this inflammatory phenotype is not apparent in liver
(data not shown), indicating that the major contribution of
PKCz to obesity-induced inflammation is restricted to its func-
tion in adipose tissue. This cytokine profile could be consistent
with a skewed M1/M2 balance of ATM toward an M1 type of hy-
perinflammatory response. To test that possibility, we measured
NOS (M1 marker) and Arg1 and Mgl2 (M2 markers) transcript
levels in WAT from HFD-fed WT and PKCz-deficient mice.
NOS mRNA levels were significantly increased in WAT from
HFD-fed knockout mice, in keeping with the proinflammatory
phenotype of PKCz-deficient mice under these conditions
(Table 1). Although few or no alterations were observed in the
levels of Arg1 in WAT from HFD-fed knockout mice, as
compared with identically treated WT mice, the levels of Mgl2
were significantly lower (Table 1), indicating a reduced M2
phenotype in PKCz/ WAT. As no alterations were observed
in IL-4 (Table 1), these results indicate that IL-4 actions on the
adipose tissue from HFD-fed PKCz/mice are impaired, giving
rise to a reducedM2 phenotype and the subsequent appearance
of a proinflammatory M1 state.
Cell-Autonomous Role of PKCz in Macrophage
Inflammatory Responses
To investigate whether the role of PKCz in M2 polarization can be
detected in ex vivo cultures of macrophages and is thus cell
autonomous, we prepared bone marrow-derived macrophages
(BMDMs) fromWT and PKCz/mice and analyzed their inflam-
matory gene signature by quantitative RT-PCR. Importantly, we
found that PKCz-deficient macrophages had reduced levels of
Arg1 andMgl2, whereas the levels of the proinflammatory genes
NOS, TNF-a, IL-6, and IL-1b were increased, as compared with
the WT controls (Table S2). These results could be interpreted to
mean that PKCz-deficient macrophages display an intrinsic and
cell-autonomous tendency toward an M1-skewed phenotype.
Therefore, we next determined whether the lack of PKCz would
impair the expression of bona fide M2 markers in response to
IL-4 in ex vivo macrophage cultures. Figures S2A–S2E show
that exposure of WT BMDMs to IL-4 triggered the expression
of PPARg and the M2 markers Arg1, Mgl2, Mgl1, and Mrc1.
This activation was significantly and reproducibly inhibited in
PKCz/ macrophages (Figures S2A–S2E), demonstrating that
PKCz plays a major role in IL-4-induced activation of the M2
phenotype. Moreover, exposure to LPS led to enhanced
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BMDMs as compared to identically treated WT cells (Figures
S2F and S2G), consistent with the concept that PKCz is neces-
sary for a tuned M1/M2 balance. IL-4 is capable of inhibiting
LPS-induced production of inflammatory cytokines (Odegaard
et al., 2008). Interestingly, the ability of IL-4 to inhibit LPS induc-
tion of TNF-a synthesis was likewise dramatically impaired in
PKCz/ BMDMs as compared with WT controls (Figure S2H).
Figures S3A–S3E demonstrate that IL-4 signaling through acti-
vation of the Arg1 promoter (a marker of M2 macrophages), as
well as the Jak1/Stat6 cascade activated by IL-4, is severely
impaired in the macrophage cell line Raw267, in which PKCz
has been depleted by shRNAi, and in PKCz-deficient BMDMs.
Collectively, these results indicate that PKCz is an important
intermediary in the acquisition of an anti-inflammatory M2
phenotype by macrophages, acting at the level of IL-4 signaling.
According to the prevailing model, impaired M2 differentiation
could account for the proinflammatory state detected in
PKCz/ adipose tissue (Table 1), which could in turn account
for the insulin-resistant state detected in these mutant mice.
Obesity-Induced Inflammation and Insulin Resistance
in Mice Lacking PKCz in the Nonhematopoietic
Compartment
Because the loss of PKCz leads to increased production of
proinflammatory cytokines in the adipose tissue of HFD-fed
mice, as well as a cell-autonomous skewing of macrophage
phenotype toward a more inflammatory state, we sought to
determine whether the loss of PKCz in the hematopoietic system
is sufficient to phenocopy the insulin-resistant and glucose-intol-
erant phenotype of total PKCz-deficient mice. Thus, we per-
formed adoptive transfer experiments to generate chimeras
with PKCz specifically deleted in the hematopoietic or nonhema-
topoietic compartments. We reconstituted lethally irradiated
PKCz-deficient and WT mice with either WT or PKCz-deficient
bone marrow cells to generate PKCz/mice with reconstituted
WT bone marrow (PKCz/ + WT-BM) and WT mice reconsti-
tuted with WT bone marrow (WT + WT-BM) or with PKCz/
bone marrow (WT + PKCz/-BM) (Figure 4A). Flow cytometry
showed that white blood cells were efficiently reconstituted
and displayed the donor genotype after bone marrow transplan-
tation (Figure 4B). To investigate reconstitution of resident
macrophages, we used PCR to genotype different tissues,
including BMDMs, 23 weeks after reconstitution. Genotyping
of BMDM and parenchymal cells indicated that BMDM cells
were almost fully derived from the donor bone marrow, whereas
the parenchymal cells were those of the recipient (Figure 4C).
The chimeras were fed a HFD for 20 weeks starting at 3 weeks
after transplantation, after which the three chimeric lines dis-
played comparable body weights (Figure 4D). We next per-
formed GTT in these mice and found that the lack of PKCz in
the nonhematopoietic compartment, but not in the hematopoi-
etic compartment, was sufficient to induce glucose intolerance
upon HFD feeding (Figure 4E). These were unexpected observa-
tions demonstrating that PKCz deficiency does not need to be
manifested in the hematopoietic system to promote glucose
intolerance in HFD-fed mice, despite the cell-autonomous role
of PKCz in M2 inflammation in macrophages and the inflamma-
tory response detected in PKCz-deficient WAT from HFD-fedPKCz knockout mice (Table S2 and Figures S2 and S3). When
ITTs were performed with these chimeras, it was apparent that
the lack of PKCz in the hematopoietic compartment was not
sufficient to trigger insulin resistance upon HFD feeding,
whereas mice with deficiency of PKCz in the nonhematopoietic
compartment displayed a defective insulin response (Figure 4F).
Morphological analysis of WAT demonstrated similar adipose
tissue volume in the three chimeras (Figure 4G). Interestingly,
mice with PKCz deficiency in the nonhematopoietic compart-
ment, but not in the hematopoietic system, show macrophage
infiltration, as determined histologically (Figure 4H) and by RT-
PCR (Figures 4I and 4J). These results indicate that the simple
deletion of PKCz in the nonhematopoietic system is sufficient
to induce WAT inflammation. Consistent with this, these mice
also had fatty liver (Figures 4K and 4L). Of note, deletion of
PKCz just in the hematopoietic compartment not only did not
favor fatty liver induction upon HFD feeding, but even slightly
reduced HFD-induced fatty liver (Figures 4K and 4L).
To identify the underlying cause of this intriguing observation,
we determined the cytokine inflammatory profile ofWAT from the
HFD-fed PKCz/ chimeras. For this, we analyzed the mRNA
levels of different inflammatory genes as described above. Inter-
estingly, WAT from mice with WT stroma and PKCz-deficient
hematopoietic systems (WT + PKCz/-BM) showed no signifi-
cant alterations in any of the inflammatory cytokines, although
Arg1 levels were reduced and NOS levels were increased (Table
S3). These results can be interpreted to mean that the loss of
PKCz in the hematopoietic compartment is not sufficient to
trigger an inflammatory phenotype in WAT in obese mice, which
correlates with normal glucose tolerance and insulin responsive-
ness in these chimeric mice (Figures 4E and 4F). The alterations
in Arg1 and NOS levels observed in these mice suggest that the
loss of PKCz in the hematopoietic compartment of HFD-fedmice
is sufficient to at least partially skew the macrophage linage
toward M1, but that this is not enough to induce an inflammatory
response that would result in glucose intolerance and insulin
resistance.
The lack of PKCz in the nonhematopoietic compartment
(PKCz/ + WT-BM) led to increased IL-6 levels in HFD-fed
chimeras with no changes in any of the other cytokines ormacro-
phage differentiation markers (Table S3). This indicates that
PKCz in the nonhematopoietic compartment exerts an anti-
inflammatory role in WAT during HFD-induced obesity. This
increase in IL-6 mRNA levels in the adipose tissue correlated
with significantly enhanced levels of circulating IL-6 in the
chimeras with PKCz deleted in the nonhematopoietic compart-
ment (Figure 4M). As the chimeric mice lacking PKCz in the non-
hematopoietic compartment are glucose intolerant, these results
suggest that IL-6 overproduction due to the lack of PKCz in the
nonhematopoietic compartment may be the conducive agent
in the glucose intolerance manifested in these HFD-fed mice
and probably the only cytokine required to induce glucose intol-
erance in obese PKCz-deficient mice.
IL-6 Overproduction in HFD-Fed PKCz-Deficient Mice
Is Necessary for Glucose Intolerance
Our data show that WAT from HFD-fed PKCz-deficient mice
have higher IL-6 mRNA levels than identically treated WT mice
(Table 1). Consistent with this, PKCz/mice fed a HFD, but notCell Metabolism 12, 65–77, July 7, 2010 ª2010 Elsevier Inc. 71
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To address the potential role of PKCz-controlled IL-6 production
in glucose intolerance during obesity, we crossed PKCz/mice
with IL-6/ mice to generate a double-knockout mouse line.
These mice were fed a HFD, as above, and GTTs and ITTs
were performed. Although IL-6/ mice showed reduced body
weight and a lower percentage change in fat weight (Figures
5A and 5B), WT, PKCz/, and double-knockout mice displayed
very similar values for both parameters (Figures 5A and 5B).
Interestingly, IL-6 ablation inhibited the glucose intolerance of
PKCz-deficient mice in the double-knockout setting (Figure 5C).
ITT experiments confirm that ablation of IL-6 in the PKCz-defi-
cient mouse line restores the glucose clearance in response to
insulin to normal values (Figure 5D). Therefore, these results
suggest that the enhanced IL-6 levels in HFD-fed PKCz/
mice are necessary and likely sufficient to induce glucose intol-
erance in obese mice and that PKCz is instrumental for the basal
repression of IL-6 production by the nonhematopoietic system
under conditions of obesity-induced inflammation. Consistent
with the role of IL-6 in PKCz/-enhanced inflammation during
obesity, we found that the loss of IL-6 in PKCz-deficient WAT
completely ablated the recruitment of macrophages (Figures
5E–5H). Interestingly, IL-6 ablation also reduced fatty liver induc-
tion by HFD feeding of PKCz-deficient mice (Figure 5I). These
results indicate that IL-6 regulation by PKCz is a key event in
HFD-induced glucose intolerance and insulin resistance.
Cell-Autonomous Effect of PKCz on IL-4-Repressed
Inflammation in Adipocytes
To determine the mechanism whereby PKCz regulates IL-6
production in the adipose tissue, we exposed WT and PKCz-
deficient primary adipocytes to lipopolysaccharide (LPS) in
the presence or absence of IL-4, after which IL-6 levels were
determined by RT-PCR. It is well established that IL-4 inhibits
inflammatory functions, which might be the basis for the induc-
tion of the type 2 anti-inflammatory state during obesity (Kang
et al., 2008; Odegaard et al., 2008). Results in Figure 6A
demonstrate that the ability of IL-4 to inhibit LPS-induced IL-6
production was severely impaired in PKCz-deficient cell
cultures. These results are in keeping with a model in which
PKCz is required for IL-4 signaling in adipocytes to dampen
proinflammatory activation during obesity. Interestingly, like in
macrophages (Figure S3), the loss of PKCz in adipocytesFigure 4. Impaired Glucose Tolerance in Mice with PKCz/ Deficienc
(A) Experimental design for the generation of hematopoietic and nonhematopoie
(B) Quantification by flow cytometry of total white blood cell reconstitution after tr
cells express the CD45.1 (Ly5.2) marker.
(C) PCR genotyping of WAT, muscle, and bone marrow-derived macrophages (B
(D) Body weight changes during experimental period.
(E) GTT.
(F) ITT.
(G) Gross morphology of epididymal adipose tissues.
(H–J) Sections of epididymal adipose tissues stained with hematoxylin and eosin
were measured by quantitative RT-PCR.
(K) Gross liver morphology.
(L) Liver sections were stained with hematoxylin and eosin.
(M and N) The amount of plasma IL-6 was measured by ELISA. Mice were faste
shown in (M). WT and PKCz/ mice fed a RD or HFD for 12 weeks are shown
*p < 0.05 versus WT + WT-BM or WT.results in the inhibition of Stat6 activation by IL-4 (Figure 6B).
This negative role of PKCz in the synthesis of IL-6 was not
only detected in primary adipocyte cultures activated by IL-4,
but also in fat pads (kept in culture for 3 days) from HFD-fed
PKCz-deficient mice. Thus, as shown in Figures 6C and 6D,
IL-6 secretion was significantly higher in cultures of epididymal
and retroperitoneal fat from HFD-fed PKCz/ mice than in
those of WT fat. IL-6/ and double-knockout fat pads
produced no IL-6, as expected (Figures 6C and 6D). To further
demonstrate that this is due to the lack of PKCz, we cultured
3T3-L1 fully differentiated adipocytes, controls, or cells with
PKCz levels reduced by siRNA for 3 days, after which the levels
of IL-6 secretion were determined. As shown in Figure 6E,
depletion of PKCz levels resulted in increased production of
IL-6. On the other hand, it has recently been shown that fatty
acids, which are abundant lipids in adipocytes, can activate
inflammation in these cells (Shi et al., 2006). The results in
Figure 6F demonstrate that PKCz-deficient primary adipocytes
secrete more IL-6 than their WT controls when exposed in
culture to myristic or palmitic acid. Collectively, these results
demonstrate that PKCz exerts a negative role on IL-6 secretion
by adipose tissue and isolated adipocyte cultures. Results in
Figure 6G show that PKCz/ precursors differentiate into
adipocytes more efficiently than do WT controls. The reasons
for these observations still need to be explored, as well as
the potential role of increased lipid accumulation in PKCz/
adipocytes in the enhanced secretion of IL-6. Future studies
will be designed to address these questions. Interestingly,
PKCz levels were severely reduced in WAT from HFD-fed
mice (Figure 6H). This strongly suggests that obesity leads to
reduction of PKCz levels, which results in increased IL-6
production and the subsequent enhancement in fatty liver
induction, glucose intolerance, and insulin resistance. In
keeping with this notion, WAT from obese Ob/Ob mice also dis-
played reduced levels of PKCz (Figure 6I).
DISCUSSION
The data reported here unveil a critical role for PKCz in adipose
tissue inflammation during HFD-induced obesity by demon-
strating that in HFD-fed obese mice, the loss of PKCz triggers
the M1 profile and inhibits the M2 profile of inflammatory cyto-
kines in adipose tissue but not in liver. As the fat content andy in the Nonhematopoietic Compartment
tic PKCz/ mice.
ansplantation. PKCz/ cells express the CD45.2 (Ly5.1) marker, whereas WT
MDMs) obtained from chimeras 23 weeks after transplantation.
(upper panel) and F4/80 (lower panel). The expression of CD68 (I) and F4/80 (J)
d overnight before collecting blood. Chimeras fed with HFD for 20 weeks are
in (N). Scale bars, 200 mm. Data are mean ±SEM of 5–7 animals per group.
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Figure 5. Restored Glucose Tolerance in HFD-Fed
PKCz/IL-6 Double-Knockout Mice
(A) WT, IL-6/, PKCz/, and PKCz/IL-6 double-
knockout (DKO) mice were fed a HFD for 12 weeks
from 7 weeks of age. In (A), changes in body weight over
12 weeks of HFD treatment are shown.
(B) Fat mass (percentage of total body weight) after
12 weeks of HFD treatment.
(C) GTT.
(D) ITT. In this ITT, 1.25 U insulin/kg body weight was
injected.
(E and F) Sections of epididymal adipose tissues were
stained with hematoxylin and eosin (E) or immunostained
to detect F4/80 (F).
(G–I) Expression of CD68 (G) and F4/80 (H) was measured
by quantitative RT-PCR. Liver sections were stained with
hematoxylin and eosin (I). Scale bars, 200 mm. Data are
mean ±SEM of 5–7 animals per group. *p < 0.05 versus
WT.
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feeding with a HFD, this strongly suggests that the anti-inflam-
matory role of PKCz in this process is not secondary to obesity,
but is manifested when mice undergo the tonic basal inflamma-
tion characteristic of the obese state. This is a very important
observation, because an increased M1/M2 balance has been
shown to trigger glucose intolerance and insulin resistance
during obesity and could explain why obese PKCz/ mice
are more glucose intolerant and insulin resistant than equally
treated obese WT mice. Surprisingly, although PKCz partici-
pates in the M1/M2 decision point in macrophages in a cell-
autonomous manner in BMDM cultures, this does not appear74 Cell Metabolism 12, 65–77, July 7, 2010 ª2010 Elsevier Inc.to account for the systemic glucose-intolerant
state of obese PKCz-deficient mice, as inacti-
vation of PKCz specific to the nonhemato-
poietic system is sufficient to induce glucose
intolerance in obese bone marrow-chimera
mice. This correlates with increased IL-6 levels,
but in contrast to PKCz knockout mice, this
increase occurs without changes in the levels
of other inflammatory cytokines. Experiments
with PKCz/IL-6 double-knockout mice demon-
strate that the simple ablation of IL-6 in
PKCz/ mice is sufficient to reverse the
glucose-intolerant phenotype of obese PKCz-
deficient mice. Interestingly, whereas some
investigators found that the loss of IL-6 led to
mature-onset obesity in animals kept on a RD
(Wallenius et al., 2002), others did not (Di Gre-
gorio et al., 2004). Here, we show that in
a pure C57BL/6 background, IL-6/ mice
display resistance to obesity induced by HFD,
in agreement with previous data (Park et al.,
2010). However, the PKCz/IL-6 double-
knockout mice display a body weight that is
similar to that of the WT or PKCz-deficient
mice when all genotypes are fed a HFD. There-
fore, the restoration of glucose tolerance and
insulin responsiveness to normal values in thedoubly mutant mice as compared to the PKCz/ mice cannot
be ascribed to differences in weight gain.
Collectively, our findings demonstrate that although the
inactivation of PKCz in both the hematopoietic and the nonhe-
matopoietic compartments is necessary to drive a type 1 inflam-
matory response, the production of IL-6 solely in the PKCz-
deficient nonhematopoietic compartment is sufficient and
necessary to induce glucose intolerance. These observations
are consistent with recent data demonstrating that JNK regula-
tion of IL-6 synthesis by adipocytes, but not by the hematopoi-
etic system, is what accounts for obesity-induced glucose intol-
erance (Sabio et al., 2008). This is important because it shows
Figure 6. Role of PKCz in IL-6 Production in Adipocytes
(A) Stromal-vascular cells were differentiated to adipocytes and treated with IL-4 (10 ng/ml) or vehicle control for 48 hr and subsequently stimulated with LPS
100 ng/ml for an additional 8 hr. Relative expression of IL-6 was quantified by quantitative RT-PCR.
(B) The phosphorylation of Stat6 after IL-4 treatment (10 ng/ml for 30 min) was measured in adipocyte-differentiated stromal-vascular cells by western blot
analysis.
(C) Epididymal adipose tissue (EP WAT).
(D) Retroperitoneal adipose tissue (RP WAT). Adipose tissues were placed in medium for 72 hr. IL-6 was not detected in medium from IL-6/ or DKO RP WAT
(ND, no detection).
(E) IL-6 secretion was measured during 3T3-L1 adipocyte differentiation after lentiviral knockdown of PKCz (shPKCzi) or in negative control cells (shNT). Cells
were treated with differentiation cocktail for 3 days.
(F) IL-6 secretion was measured in fully adipocyte-differentiated stromal-vascular cells after stimulation with different free fatty acids for 16 hr. Ctrl, control; MA,
myristic acid (50 mM); PA, palmitic acid (50 mM). In (C)–(F), IL-6 secretion was measured by ELISA.
(G) Adipocyte-differentiated stromal-vascular cells were stained with oil red O at day 8 after stimulation with differentiation cocktail.
(H) PKCz protein expression was measured by western blot analysis of adipose tissue from RD- or HFD-fed WT mice. Actin was used as a loading control.
(I) The expression of PKCz protein was measured in adipose tissue from age-matched WT or ob/ob mice. Tubulin was used as a loading control. Scale bars,
200 mm. Data are presented as mean ±SEM. *p < 0.05.
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cell type is essential during obesity-induced inflammation and
its associated impact on glucose metabolism. Here, we show
that despite the hyperactivation of inflammation in the obese
PKCz knockout mice, only the IL-6 produced by the nonhemato-
poietic systems is necessary and sufficient to promote glucoseintolerance in these mice. In the case of PKCz, the study of
adipocyte primary cultures fromknockoutmice revealed amech-
anismwhereby PKCz plays a critical role in the anti-inflammatory
effects of type 2 cytokines, such as IL-4, in the function of adipo-
cytes as inflammatory cells in obesity. This is reminiscent of our
previously reported evidence showing that PKCz’s role in IL-4Cell Metabolism 12, 65–77, July 7, 2010 ª2010 Elsevier Inc. 75
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PKCz in Obesity-Induced Inflammationsignal transduction is also important for another IL-4 function,
Th2 differentiation and allergic airway inflammation (Dura´n
et al., 2004; Martin et al., 2005). In this way, PKCz emerges as
a key player in several inflammatory processes in which an
adequate balance in the response is required for normal homeo-
static control of metabolism.
EXPERIMENTAL PROCEDURES
Mice
All mice used in the experiments were bred on aC57BL/6 background formore
than 12 generations, and all experiments involved comparisons among litter-
mates. IL-6 knockout mice were purchased from The Jackson Laboratory.
All procedures were approved by the Institutional Animal Care and Utilization
Committees at the University of Cincinnati, in accordance with the NIH guide
for the care and use of laboratory animals.
Glucose Tolerance and Insulin Tolerance Testing
To assess glucose tolerance and insulin sensitivity, mice were first subjected
to overnight fasting and injected intraperitoneally with 2 g glucose/kg body wt
(25% D-glucose [Sigma, St. Louis] in 0.9% saline) for the GTT and 0.75 U or
1.25 U insulin/kg body weight (100 U/ml Humalog Pen [Lily; Indianapolis, IN])
for the ITT. Tail blood glucose levels (mg/dl) were measured by using a hand-
held glucometer (ACCU-CHEK Aviva [Roche; Indianapolis, IN]).
Generation of Adoptive Transfer Chimeras
To generate chimeras, mice were administered 7 Gy and 4.75 Gy of ionizing
radiation at 3 hr intervals and injected through the tail vein with 5 3 106 whole
bone marrow cells prepared fromWT or PKCz/mice. Mice were maintained
for 3 weeks on normal chow including doxycycline (200 mg/kg) to allow for
bone marrow reconstitution. Mice were placed on a HFD for 20 weeks after
termination of antibiotic treatment. To quantify reconstitution efficiency, we
used congenic donors and recipients that differed at the Ly5.1/Ly5.2 locus.
Whole blood cells were collected and analyzed by flow cytometric analysis
of congenic Ly5.1 (CD45.2-FITC; BD PharMingen; San Diego, CA) and Ly5.2
(CD45.1-PE; BD PharMingen) markers. Genomic DNA was extracted from
tissues or cultured BMDMs and genotyped by PCR.
Additional experimental procedures can be found in the Supplemental Infor-
mation.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, three tables, and three figures and can be found
with this article online at doi:10.1016/j.cmet.2010.05.003.
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